Clinical Trial Detail

NCT ID	NCT04187833
Title	Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Case Comprehensive Cancer Center
Indications	melanoma
Therapies	Nivolumab + Talazoparib
Age Groups:	adult senior